Key facts
- 4TEEN4 Pharmaceuticals’s last known valuation is $33.7M (Dec 2019).
- It has raised $118.7M; the latest was Later Stage VC ($63.8M) in Nov 2025.
- Notable investors include NRW.Bank, Brandenburg Kapital, HBM Partners, Wellington Partners, HBM Healthcare Investments — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for 4TEEN4 Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for 4TEEN4 Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 4TEEN4 Pharmaceuticals
Developer of precision medicine designed to improve outcomes in critical care for acute cardiovascular complications. The company offers targeted therapies focused on restoring cardiac and vascular function, enabling patients with life-threatening cardiovascular conditions to benefit from improved survival and treatment effectiveness.
- Sector
- Healthcare
- HQ
- Hennigsdorf, Germany
- Founded
- 2013
- Employees
- 35
- Website
- 4teen4.de/
- Ownership
- Privately Held (backing)
4TEEN4 Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 4TEEN4 Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 4TEEN4 Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.